cbdMD, Inc 8-K, filed Oct 1, 2020
cbdMD, Inc. (YCBD)
8-K
2020-10-01
For: 2020-10-01
View Original
Added on
April 08, 2026
About this 8-K
cbdMD, Inc filed this 8-K on October 1, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported)
October 1,
2020
cbdMD, Inc.
(Exact name of registrant as specified in its charter)
|
North Carolina
|
001-38299
|
47-3414576
|
|
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
8845 Red Oak Blvd, Charlotte, NC 28217
(Address of principal executive offices)(Zip Code)
Registrant's
telephone number, including area code: (704) 445-3060
_______________________________________
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
common
|
YCBD
|
NYSE
American
|
|
8%
Series A Cumulative Convertible Preferred Stock
|
YCBD PR
A
|
NYSE
American
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☑
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD
Disclosure.
On
October 1, 2020 cbdMD, Inc. released an updated investor relations
presentation. A copy of the updated presentation is furnished as
Exhibit 99.1 to this report.
Pursuant to General
Instruction B.2 of Form 8-K, the information in this Item 7.01 of
Form 8-K, including Exhibit 99.1, is being furnished and shall not
be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise be subject to the
liabilities of that section, nor is it incorporated by reference
into any filing of cbdMD, Inc. under the Securities Act of 1933 or
the Securities Exchange Act of 1934, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing.
Item 9.01 Financial
Statements and Exhibits.
(d)
Exhibits.
|
|
|
|
|
Incorporated by Reference
|
|
Filed or
Furnished
Herewith
|
||||
|
No.
|
|
Exhibit Description
|
|
Form
|
|
Date Filed
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor
relations presentation dated October 1, 2020
|
|
|
|
|
|
|
|
Furnished
|
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
cbdMD,
Inc.
|
|
|
|
|
|
|
Date:
October 1, 2020
|
By:
|
/s/
Martin A. Sumichrast
|
|
|
|
Martin
A. Sumichrast, co- Chief Executive Officer
|
3
Exhibit
99.1
